Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnel
S. M. Zhang, C. B. Paulin, M. Michel, P. Marttila, M. Yagüe-Capilla, H. C. Bwanika, H. Shu, R. Papagudi Vekatram, E. Wiita, A.-S. Jemth, I. Almlöf, O. Loseva, F. Ortis, C. Dirks, T. Koolmeister, E. Linde, S. Lee, S. Llona-Minguez, M. Haraldsson, K. Strömberg, E. J. Homan, M. Scobie, T. Lundbäck, T. Helleday, S. G. Rudd
Abstract
Sterile alpha motif and histidine-aspartic acid domain containing protein-1 (SAMHD1) is a deoxynucleoside triphosphate (dNTP) triphosphohydrolase central to cellular nucleotide pool homeostasis. Recent literature has also demonstrated how SAMHD1 can detoxify chemotherapy metabolites thereby controlling their clinical responses. To further understand SAMHD1 biology and to investigate the potential of targeting this enzyme as a neoadjuvant to existing chemotherapies we set out to discover selective small molecule-based inhibitors of SAMHD1. Here we report a discovery pipeline encompassing a biochemical screening campaign and a set of complementary biochemical, biophysical, and cell-based readouts for further characterisation of the screen output. The identified hit compound TH6342 and its analogues, accompanied by their inactive negative control analogue TH7126, demonstrated specific, low M potency in inhibiting the hydrolysis of both natural substrates and nucleotide analogue therapeutics, shown using complementary enzyme-coupled and direct enzymatic activity assays. Their mode of inhibition was subsequently detailed by coupling kinetic studies with thermal shift assays, where TH6342 and analogues were shown to engage with pre-tetrameric SAMHD1 and deter the oligomerisation and allosteric activation of SAMHD1 without occupying nucleotide binding pockets. We further outline the development and application of multiple cellular assays for assessing cellular target engagement and associated functional effects, including CETSA and an in-cell dNTP hydrolase activity assay, which highlighted future optimisation strategies of this chemotype. In summary, with a novel mode of inhibition, TH6342 and analogues broaden the set of tool compounds available in deciphering SAMHD1 enzymology and functions, and furthermore, the discovery pipeline reported herein represents a thorough framework for future SAMHD1 inhibitor development. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=96 SRC="FIGDIR/small/524275v1_ufig1.gif" ALT="Figure 1"> View larger version (34K): org.highwire.dtl.DTLVardef@dc706forg.highwire.dtl.DTLVardef@59a9b4org.highwire.dtl.DTLVardef@9473e2org.highwire.dtl.DTLVardef@4427dc_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Allosteric substrate activation of SAMHD1 shapes deoxynucleotide triphosphate imbalances by interconnecting the depletion and biosynthesis of different dNTPs
C. McCown, C. H. Yu, D. N. Ivanov·bioRxiv·Nov 14, 2023
- The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1
K. M. Knecht, O. Buzovetsky, … Y. Xiong·bioRxiv·Apr 6, 2018
- Phosphorylation of SAMHD1 Thr592 increases C-terminal domain dynamics, tetramer dissociation, and ssDNA binding kinetics
B. Orris, K. W. Huynh, … J. T. Stivers·bioRxiv·Apr 5, 2022
- SUMOylation of SAMHD1 at Lysine 595 is required for HIV-1 restriction in non-cycling cells
C. Martinat, A. Cormier, … A. Zamborlini·bioRxiv·Jun 4, 2020
- Transition metal activation reframes SAMHD1 regulation
Logan A Calderone, Anthony S. Gizzi, … Maria‐Eirini Pandelia·ACS Chemical BiologyPeer-reviewed·Jul 15, 2026
- Guanine-containing ssDNA and RNA induce dimeric and tetrameric SAMHD1 in cryo-EM and binding studies
B. Orris, M. W. Sung, … J. T. Stivers·bioRxiv·Jun 15, 2023